NCT02960880View on ClinicalTrials.gov

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists

CompletedOBSERVATIONAL
Enrollment

99,999

Participants

Timeline

Start Date

October 15, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Atrial Fibrillation
Interventions
DRUG

Rivaroxaban (Xarelto, BAY597939)

15mg, 20mg

DRUG

Phenprocoumon (branded and generics)

Individually adjusted dose

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Bayer

INDUSTRY